These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6292610)

  • 1. Unexpected opioid activity in a known class of drug.
    Römer D; Büscher HH; Hill RC; Maurer R; Petcher TJ; Zeugner H; Benson W; Finner E; Milkowski W; Thies PW
    Life Sci; 1982 Sep 20-27; 31(12-13):1217-20. PubMed ID: 6292610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tifluadom, a kappa-opiate agonist, acts as a peripheral cholecystokinin receptor antagonist.
    Chang RS; Lotti VJ; Chen TB; Keegan ME
    Neurosci Lett; 1986 Dec; 72(2):211-4. PubMed ID: 3027627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction of the two isomers of the opioid benzodiazepine tifluadom with mu-, delta-, and kappa-binding sites and their analgesic and intestinal effects in rats.
    Petrillo P; Amato M; Tavani A
    Neuropeptides; 1985 Feb; 5(4-6):403-6. PubMed ID: 2860598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a kappa-agonist-like antinociceptive action of tifluadom.
    Upton N; Gonzalez JP; Sewell RD
    Neuropharmacology; 1983 Oct; 22(10):1241-2. PubMed ID: 6316195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kappa-opioid diuretic effects of tifluadom, a benzodiazepine opioid agonist.
    Leander JD
    J Pharm Pharmacol; 1984 Aug; 36(8):555-6. PubMed ID: 6148404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD117302: a selective agonist for the kappa-opioid receptor.
    Clark CR; Birchmore B; Sharif NA; Hunter JC; Hill RG; Hughes J
    Br J Pharmacol; 1988 Mar; 93(3):618-26. PubMed ID: 2836012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Veber DF; Freidinger RM; Chang RS; Chen TB; Lotti VJ
    J Med Chem; 1990 Jan; 33(1):450-5. PubMed ID: 2153212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the opioid benzodiazepine tifluadom and its optical isomers on spontaneous locomotor activity of mice.
    Ruhland M; Zeugner H
    Life Sci; 1983; 33 Suppl 1():631-4. PubMed ID: 6319918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the opioid-benzodiazepine, tifluadom, on ingestive behaviors.
    Morley JE; Levine AS; Grace M; Kneip J; Zeugner H
    Eur J Pharmacol; 1983 Sep; 93(3-4):265-9. PubMed ID: 6315453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
    Anzini M; Canullo L; Braile C; Cappelli A; Gallelli A; Vomero S; Menziani MC; De Benedetti PG; Rizzo M; Collina S; Azzolina O; Sbacchi M; Ghelardini C; Galeotti N
    J Med Chem; 2003 Aug; 46(18):3853-64. PubMed ID: 12930147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cations on binding, in membrane suspensions, of various opioids at mu-sites of rabbit cerebellum and kappa-sites of guinea-pig cerebellum.
    Kosterlitz HW; Paterson SJ; Robson LE; Traynor JR
    Br J Pharmacol; 1987 Jun; 91(2):431-7. PubMed ID: 3038237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locomotor depression by the opioid benzodiazepine tifluadom in mice.
    Castellano C; Pavone F; Sansone M
    Arch Int Pharmacodyn Ther; 1984 Aug; 270(2):318-23. PubMed ID: 6091579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further demonstration of kappa opioid binding sites in the brain: evidence for heterogeneity.
    Su TP
    J Pharmacol Exp Ther; 1985 Jan; 232(1):144-8. PubMed ID: 2856939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICI 204448: a kappa-opioid agonist with limited access to the CNS.
    Shaw JS; Carroll JA; Alcock P; Main BG
    Br J Pharmacol; 1989 Apr; 96(4):986-92. PubMed ID: 2568146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: further evidence of kappa receptor heterogeneity.
    Heyliger SO; Jackson C; Rice KC; Rothman RB
    Synapse; 1999 Dec; 34(4):256-65. PubMed ID: 10529720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of kappa opioid binding using dynorphin A1-13 and U69,593 in the rat brain.
    Devlin T; Shoemaker WJ
    J Pharmacol Exp Ther; 1990 May; 253(2):749-59. PubMed ID: 1971019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reverse stereoselectivity of opiate and benzodiazepine receptors for the opioid benzodiazepine tifluadom.
    Kley H; Scheidemantel U; Bering B; Müller WE
    Eur J Pharmacol; 1983 Mar; 87(4):503-4. PubMed ID: 6303803
    [No Abstract]   [Full Text] [Related]  

  • 18. CI-977, a novel and selective agonist for the kappa-opioid receptor.
    Hunter JC; Leighton GE; Meecham KG; Boyle SJ; Horwell DC; Rees DC; Hughes J
    Br J Pharmacol; 1990 Sep; 101(1):183-9. PubMed ID: 2178014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kappa-opiate-induced diuresis and changes in blood pressure: demonstration of receptor stereoselectivity using (+)- and (-)-tifluadom.
    Ureta H; López LF; Pérez A; Huidobro-Toro JP
    Eur J Pharmacol; 1987 Mar; 135(3):289-95. PubMed ID: 3034631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
    Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
    J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.